SM04554
weak data
The Dose Guy’s verdictSep 1, 20261 source
A genuinely different idea for hair loss, targeting the Wnt pathway to wake dormant follicles instead of blocking androgens. SM04554 went through phase 2 with modest signals per trial registries and press releases, but the program has gone quiet, the published evidence is almost nonexistent, and you cannot source it anyway. A compound to watch from the outside, not one to run.
What it is
A topical small molecule that targets the Wnt signaling pathway, the cellular machinery that governs whether a hair follicle stays dormant or enters a new growth cycle. Where finasteride and the topical antiandrogens like RU58841 and pyrilutamide work by fighting the hormone that shrinks follicles, SM04554 tries to flip the regrowth switch directly. Samumed, now Biosplice Therapeutics, developed it and took it through clinical trials. The mechanism is different from anything else on the hair-loss shelf, which is why it is on this page.
What the research shows
The published record is almost empty:
Realistic protocols
SM04554 is not circulating as a research chemical. It was a clinical-stage drug candidate, not a powder you can source from a vendor. The dosing information that exists lives in trial registries and press releases, not published literature. There is no community protocol to write.
If the Biosplice program publishes data and advances, that changes. For now, the honest answer is: there is nothing to run. If your interest is the Wnt pathway rather than antiandrogen blockade, minoxidil has some Wnt-modulatory activity alongside its primary vasodilator effect, and decades of human data behind it.
Side effects
No human adverse-event data has been published:
